IAPP and type 2 diabetes mellitus: Since it is possible that Aβ evolvability might be promoted not only by amylin protofibrils but also by other molecules, such as cholesterol and catecholamines, it follows that disease-modifying therapies targeted against other metabolic syndrome disorders in addition to T2DM, especially anti-hypertension agents, might increase overall treatment efficacy.